Friday, November 6, 2020
- 9:00AM-11:00AM
-
Abstract Number: 0226
Similar Efficacy of Sarilumab Monotherapy (MONARCH) vs Sarilumab and Methotrexate Combination Therapy (MOBILITY B) in Patients with Rheumatoid Arthritis
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0337
Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 0068
Single Cell RNA-seq to Characterize Monocyte Subtypes in the Autoinflammatory Interferonopathy, SAVI and the Inflammasomopathy, NOMID
Innate Immunity Poster- 9:00AM-11:00AM
-
Abstract Number: 0327
Skin Involvement in Psoriatic Arthritis (PsA) – The Incremental Impact of Psoriasis on Quality of Life, Disability and Work Productivity: Real-world Survey in US and Europe
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 0291
SLAMF7 and CD38 on NK Cells Represent Potential New Therapeutic Targets for Systemic Lupus Erythematosus
SLE – Etiology & Pathogenesis Poster- 9:00AM-11:00AM
-
Abstract Number: 0303
SLE Patients Stratify into Distinct Clusters Based on Their Peripheral Blood Immunologic Phenotype During Acute Flare
SLE – Etiology & Pathogenesis Poster- 9:00AM-11:00AM
-
Abstract Number: 0262
SLE Pregnancies: C4 as Predictor of Flares and Adverse Pregnancy Outcomes
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations- 9:00AM-11:00AM
-
Abstract Number: 0046
Socioeconomic Disparities in Functional Status Among RA Patients: A Longitudinal Analysis Using RISE Data
Healthcare Disparities in Rheumatology Poster- 9:00AM-11:00AM
-
Abstract Number: 0364
Subcutaneous Secukinumab 150 Mg Provides Sustained Relief in Total and Nocturnal Back Pain, Morning Stiffness, Fatigue, and Low Disease Activity in Patients with Active Ankylosing Spondylitis: End-of-study (5-year) Data from the MEASURE 2 Trial
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0272
Superior Discrimination Between LLDAS and DORIS Remission with Modification of Prednisolone Dose Threshold
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations- 9:00AM-11:00AM
-
Abstract Number: 0357
Suppressing Inflammation Rather Than Lowering the Disease Activity Score Should Be Targeted During TNF Inhibitor Treatment to Slow Radiographic Changes in Patients with Ankylosing Spondylitis
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0419
Survival and Prevalent Comorbidities in Polymyalgia Rheumatica
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I- 9:00AM-11:00AM
-
Abstract Number: 0214
Sustainability of Response Between Upadacitinib and Adalimumab Among Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
RA – Treatments Poster I: RA Treatments & Their Safety